Quoin reports positive QRX003 interim data and secures FDA approvals for PSS.

Quoin Pharmaceuticals reported statistical significance for QRX003 in Netherton Syndrome, received FDA clearance for Peeling Skin Syndrome, and secured a $50M private placement to fund development.